Roivant director sells 4,938 shares at ~$40

A Roivant Sciences director disclosed pre-planned open-market sales totaling 4,938 common shares on September 15, 2026 under a Rule 10b5-1 trading plan.

Available on EDGAR 09/17/2026 - 06:43 PM EDT Accepted by SEC EDGAR 09/17/2026 - 06:43 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Roivant Sciences Ltd. (ROIV) director Melissa B. Epperly reported open-market sales of Roivant Common Shares on September 15, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on March 30, 2026. She sold 4,338 shares at a weighted average price of $39.65 and 600 shares at a weighted average price of $40.38, with each sale executed in multiple trades within disclosed price ranges.

Insider Trade Summary 10b5-1

Net Seller: 4,938 shares

Net Sell 2 txns

Insider Epperly Melissa B,

Role Director

Sold 4,938 shs ($196K)

Type	Security	Shares	Price	Value
Sale	Common Shares F1	4,338	$39.65	$172K
Sale	Common Shares F2	600	$40.38	$24K

Holdings After Transaction: Common Shares — 9,900 shares (Direct)

Footnotes (2)

1. F1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.25 to $40.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026.
2. F2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.25 to $40.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026.

Key Figures

Shares sold at $39.65 weighted average: 4,338 shares Shares sold at $40.38 weighted average: 600 shares Total shares sold: 4,938 shares +3 more

6 metrics

Shares sold at $39.65 weighted average 4,338 shares Open-market sale of Common Shares on September 15, 2026 under Rule 10b5-1 plan

Shares sold at $40.38 weighted average 600 shares Open-market sale of Common Shares on September 15, 2026 under Rule 10b5-1 plan

Total shares sold 4,938 shares Aggregate of reported sales on September 15, 2026

Price range for first sale block $39.25–$40.15 per share Range of individual trade prices for 4,338-share block

Price range for second sale block $40.25–$40.50 per share Range of individual trade prices for 600-share block

Rule 10b5-1 trading plan adoption date March 30, 2026 Plan under which the reported sales were executed

Key Terms

Rule 10b5-1 trading plan, weighted average price, Common Shares

3 terms

Rule 10b5-1 trading plan regulatory

"These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Common Shares financial

"full information regarding the number of Common Shares sold at each separate price"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Roivant Sciences (ROIV) report for Melissa B. Epperly?

Roivant Sciences reported that director Melissa B. Epperly sold a total of 4,938 Common Shares on September 15, 2026 in open-market transactions, as disclosed in a Form 4 filing.

At what prices were the ROIV shares sold by the director on September 15, 2026?

Epperly sold 4,338 shares at a weighted average price of $39.65 (within a $39.25–$40.15 range) and 600 shares at a weighted average price of $40.38 (within a $40.25–$40.50 range), each in multiple transactions.

How many Roivant Sciences (ROIV) shares did the director sell in total?

The Form 4 shows that Melissa B. Epperly sold a total of 4,938 Common Shares of Roivant Sciences Ltd. on September 15, 2026 across two reported transaction lines.

Were Melissa B. Epperly’s ROIV share sales made under a Rule 10b5-1 plan?

Yes. The filing states that these sales were effected pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026, and the Form 4’s Rule 10b5-1 checkbox is affirmed.

Were the ROIV insider sales single trades or multiple trades at different prices?

Each line item represents multiple transactions. The filing explains that the reported prices are weighted averages and that the underlying trades occurred within specified price ranges, with full trade-by-trade detail available on request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Epperly Melissa B,

(Last) (First) (Middle)

C/O ROIVANT SCIENCES LTD.

7TH FLOOR, 50 BROADWAY

(Street)

LONDON SW1H 0DB

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	09/15/2026		S		4,338	D	$39.65	10,500(1)	D
Common Shares	09/15/2026		S		600	D	$40.38	9,900(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.25 to $40.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026.

2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.25 to $40.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026.

Remarks:

	By: /s/ Sam Kaplan, as Attorney-in-Fact for Melissa Epperly	09/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)